Search Results - "NAYLOR, Rochelle N"

The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing by GoodSmith, Matthew S, Skandari, M Reza, Huang, Elbert S, Naylor, Rochelle N

“…In the U.S., genetic testing for maturity-onset diabetes of the young (MODY) is frequently delayed because of difficulty with insurance coverage. Understanding…”
Get full text

Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis by Letourneau, Lisa R, Carmody, David, Wroblewski, Kristen, Denson, Anna M, Sanyoura, May, Naylor, Rochelle N, Philipson, Louis H, Greeley, Siri Atma W

“…Diabetes in childhood has been associated with increased morbidity and mortality, but the risks for diabetes in infancy remain unclear. Cases with onset of…”
Get full text

Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes by Thurber, Brian W., Carmody, David, Tadie, Elizabeth C., Pastore, Ashley N., Dickens, Jazzmyne T., Wroblewski, Kristen E., Naylor, Rochelle N., Philipson, Louis H., Greeley, Siri Atma W.

“…Aims/hypothesis Individuals with heterozygous activating mutations of the KCNJ11 gene encoding a subunit of the ATP-sensitive potassium channel (KATP) can…”
Get full text

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated by Carmody, David, Naylor, Rochelle N., Bell, Charles D., Berry, Shivani, Montgomery, Jazzmyne T., Tadie, Elizabeth C., Hwang, Jessica L., Greeley, Siri Atma W., Philipson, Louis H.

“…Aims GCK-MODY leads to mildly elevated blood glucose typically not requiring therapy. It has been described in all ethnicities, but mainly in Caucasian…”
Get full text

GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants by Sanyoura, May, Letourneau, Lisa, Knight Johnson, Amy E., del Gaudio, Daniela, Greeley, Siri Atma W., Philipson, Louis H., Naylor, Rochelle N.

“…We report on 134 unique GCK variants in 217 families, including 27 unpublished variants, identified in the US Monogenic Diabetes Registry in the last decade…”
Get full text

Sulfonylurea Treatment Before Genetic Testing in Neonatal Diabetes: Pros and Cons by Carmody, David, Bell, Charles D, Hwang, Jessica L, Dickens, Jazzmyne T, Sima, Daniela I, Felipe, Dania L, Zimmer, Carrie A, Davis, Ajuah O, Kotlyarevska, Kateryna, Naylor, Rochelle N, Philipson, Louis H, Greeley, Siri Atma W

“…Context: Diabetes in neonates nearly always has a monogenic etiology. Earlier sulfonylurea therapy can improve glycemic control and potential…”
Get full text

Investigator and participant expectations for returning non-genetic results: insights from the Rare and Atypical Diabetes Network (RADIANT) study by Noohi, Forough, Sundaresan, Manu S, Naylor, Rochelle N, Ross, Lainie Friedman

“…The Rare and Atypical DIAbetes NeTwork (RADIANT) aims to discover the underlying pathoetiology of atypical diabetes by conducting both genotyping and…”
Get full text

Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT) by Tosur, Mustafa, Gandolfo, Laura, Balasubramanyam, Ashok, Naylor, Rochelle N, Pollin, Toni I, Rasouli, Neda, Cromer, Sara J, Buse, John B, Redondo, Maria J

“…Diabetes mellitus in underrepresented racial and ethnic groups (URG) is rapidly increasing in incidence and has worse outcomes than diabetes in non-Hispanic…”
Get full text

Genetics and pathophysiology of neonatal diabetes mellitus by Naylor, Rochelle N, Greeley, Siri Atma W, Bell, Graeme I, Philipson, Louis H

“…Neonatal diabetes mellitus (NDM) is the term commonly used to describe diabetes with onset before 6 months‐of‐age. It occurs in approximately one out of every…”
Get full text

Clinical Management of Women with Monogenic Diabetes During Pregnancy by Dickens, Laura T., Naylor, Rochelle N.

“…Purpose of Review Monogenic diabetes accounts for 1–2% of all diabetes cases, but is frequently misdiagnosed as type 1, type 2, or gestational diabetes…”
Get full text

1035-P: Area Deprivation Index and Rates of Specialty Care in Monogenic Diabetes Registry Participants by SON, RACHEL G., NAYLOR, ROCHELLE N., GROUP UNIVERSITY OF CHICAGO MONOGENIC DIABETES REGISTRY, STUDY

“…While diabetes is one of the most common chronic medical conditions, monogenic forms of diabetes represent a rare subtype, and face barriers to timely…”
Get full text

Diagnosis, treatment and disclosure: A qualitative exploration of participant challenges in a Monogenic Diabetes Registry by Noohi, Forough, Sundaresan, Manu S., Naylor, Rochelle N., Ross, Lainie Friedman

“…Maturity-onset diabetes of the young (MODY) represents a heterogenous group of monogenic diabetes. Despite its autosomal dominant inheritance, many MODY…”
Get full text

Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY) by Arosemena, Marilyn, Salguero, Maria V, Naylor, Rochelle N, Wroblewski, Kristen, Tasali, Esra, Philipson, Louis H

“…To examine sleep patterns in adults with maturity-onset diabetes of the young (MODY). Adults with glucokinase (GCK)-MODY and transcription factor (TF)-related…”
Get full text

Cost-Effectiveness of MODY Genetic Testing: Translating Genomic Advances Into Practical Health Applications by NAYLOR, Rochelle N, JOHN, Priya M, WINN, Aaron N, CARMODY, David, GREELEY, Siriatma W, PHILIPSON, Louis H, BELL, Graeme I, HUANG, Elbert S

“…OBJECTIVE To evaluate the cost-effectiveness of a genetic testing policy for HNF1A-, HNF4A-, and GCK-MODY in a hypothetical cohort of type 2 diabetic patients…”
Get full text

Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis by Laiteerapong, Neda, Cooper, Jennifer M, Skandari, M Reza, Clarke, Philip M, Winn, Aaron N, Naylor, Rochelle N, Huang, Elbert S

“…Intensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established, cost-effective standard of care. However, guidelines…”
Get full text

1116-P: Enrollment of Racial/Ethnic Minorities in the Rare and Atypical Diabetes Network (RADIANT) by TOSUR, MUSTAFA, GANDOLFO, LAURA, BALASUBRAMANYAM, ASHOK, NAYLOR, ROCHELLE N., POLLIN, TONI I., RASOULI, NEDA, BUSE, JOHN B., REDONDO, MARIA J.

“…RADIANT is an NIH study of people with uncharacterized forms of atypical diabetes mellitus (DM) in the US. RADIANT participants consent online and progress…”
Get full text

Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity by Harris, Anastasia, Naylor, Rochelle N

“…Monogenic diabetes affects approximately 120,000 people in the United States but continues to be misdiagnosed. Within the pediatric population, 1% to 3% of…”
Get more information

Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) by Gregory, Justin M, Smith, T Jordan, Slaughter, James C, Mason, Holly R, Hughey, Curtis C, Smith, Marta S, Kandasamy, Balamurugan, Greeley, Siri Atma W, Philipson, Louis H, Naylor, Rochelle N, Letourneau, Lisa R, Abumrad, Naji N, Cherrington, Alan D, Moore, Daniel J

“…Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions…”
Get full text

127-LB: Characteristics of INS-MODY Participants in a National Diabetes Registry by MCCAULEY, MARY, KORKMAZ, SERENA, LETOURNEAU-FREIBERG, LISA R., NAYLOR, ROCHELLE N., GREELEY, SIRI ATMA W.

“…Introduction: Maturity onset diabetes of the young (MODY) may represent 2-5% of diabetes under 30-35 years. Rarely MODY may be due to mutation in the INS gene…”
Get full text

Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry by Dickens, Laura T., Letourneau, Lisa R., Sanyoura, May, Greeley, Siri Atma W., Philipson, Louis H., Naylor, Rochelle N.

“…Aims GCK-MODY is characterized by mild hyperglycemia. Treatment is not required outside of pregnancy. During pregnancy, insulin treatment is recommended if…”
Get full text